313 research outputs found
Integrating process and factor understanding of environmental innovation by water utilities
Innovations in technology and organisations are central to enabling the water sector to adapt to major environmental changes such as climate change, land degradation or drinking water pollution. While there are literatures on innovation as a process and on the factors that influence it, there is little research that integrates these. Development of such an integrated understanding of innovation is central to understanding how policy makers and organisations can stimulate and direct environmental innovation. In the research reported here a framework is developed that enables such an integrated analysis of innovation process and factors. From research interviews and the literature twenty factors were identified that affect the five stages of the environmental innovation process in English and Welsh water utilities. The environmental innovations investigated are measures taken by water utilities to reduce or prevent pollution in drinking water catchments rather than technical measures to treat water. These Source Control Interventions are similar to other environmental innovations, such as ecosystem and species conservation, in that they emphasise the mix of technology, management and engagement with multiple actors. Results show that in water utilities direct performance regulation and regulation that raises awareness of a ‘performance’ gap as a ‘problem’ can stimulate innovation, but only under particular organisational, natural physical and regulatory conditions. The integrated framework also suggests that while flexible or framework legislation (e.g. Water Framework Directive) does not stimulate innovation in itself, it has shaped the option spaces and characteristics of innovations selected towards source control instead of technical end-of-pipe solutions
Magnetic suspension and balance system advanced study, 1989 design
The objectives are to experimentally confirm several advanced design concepts on the Magnetic Suspension and Balance Systems (MSBS). The advanced design concepts were identified as potential improvements by Madison Magnetics, Inc. (MMI) during 1984 and 1985 studies of an MSBS utilizing 14 external superconductive coils and a superconductive solenoid in an airplane test model suspended in a wind tunnel. This study confirmed several advanced design concepts on magnetic suspension and balance systems. The 1989 MSBS redesign is based on the results of these experiments. Savings of up to 30 percent in supporting magnet ampere meters and 50 percent in energy stored over the 1985 design were achieved
Augmenting Auto-context with Global Geometric Features for Spinal Cord Segmentation
Abstract. Anatomical shape variations are typically difficult to model and parametric or hand-crafted models can lead to ill-fitting segmentations. This difficulty can be addressed with a framework like autocontext, that learns to jointly detect and regularize a segmentation. However, mis-segmentation can still occur when a desired structure, such as the spinal cord, has few locally distinct features. High-level knowledge at a global scale (e.g. an MRI contains a single connected spinal cord) is needed to regularize these candidate segmentations. To encode highlevel knowledge, we propose to augment the auto-context framework with global geometric features extracted from the detected candidate shapes. Our classifier then learns these high-level rules and rejects falsely detected shapes. To validate our method we segment the spinal cords from 20 MRI volumes composed of patients with and without multiple sclerosis and demonstrate improvements in accuracy, speed, and manual effort required when compared to state-of-the-art methods.
Pamela: development of the RF system for a non-relativistic non-scaling FFAG
The PAMELA project(Particle Accelerator For MEdical
Applications) currently consists of the design of a particle
therapy facility. The project, which is in the design phase,
contains Non-Scaling FFAG, particle accelerator capable
of rapid beam acceleration, giving a pulse repetition rate of
1kHz, far beyond that of a conventional synchrotron. To
realise the repetition rate, a key component of the accelerator
is the rf accelerating system. The combination of a high
energy gain per turn and a high repetition rate is a significant
challenge. In this paper, options for the rf system of
the proton ring and the status of development are presented
Inhibiting heat-shock protein 90 reverses sensory hypoalgesia in diabetic mice
Increasing the expression of Hsp70 (heat-shock protein 70) can inhibit sensory neuron degeneration after axotomy. Since the onset of DPN (diabetic peripheral neuropathy) is associated with the gradual decline of sensory neuron function, we evaluated whether increasing Hsp70 was sufficient to improve several indices of neuronal function. Hsp90 is the master regulator of the heat-shock response and its inhibition can up-regulate Hsp70. KU-32 (N-{7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyl-tetrahydro-2H-pyran-2-yloxy]-8-methyl-2-oxo-2H-chromen-3-yl}acetamide) was developed as a novel, novobiocin-based, C-terminal inhibitor of Hsp90 whose ability to increase Hsp70 expression is linked to the presence of an acetamide substitution of the prenylated benzamide moiety of novobiocin. KU-32 protected against glucose-induced death of embryonic DRG (dorsal root ganglia) neurons cultured for 3 days in vitro. Similarly, KU-32 significantly decreased neuregulin 1-induced degeneration of myelinated Schwann cell DRG neuron co-cultures prepared from WT (wild-type) mice. This protection was lost if the co-cultures were prepared from Hsp70.1 and Hsp70.3 KO (knockout) mice. KU-32 is readily bioavailable and was administered once a week for 6 weeks at a dose of 20 mg/kg to WT and Hsp70 KO mice that had been rendered diabetic with streptozotocin for 12 weeks. After 12 weeks of diabetes, both WT and Hsp70 KO mice developed deficits in NCV (nerve conduction velocity) and a sensory hypoalgesia. Although KU-32 did not improve glucose levels, HbA1c (glycated haemoglobin) or insulin levels, it reversed the NCV and sensory deficits in WT but not Hsp70 KO mice. These studies provide the first evidence that targeting molecular chaperones reverses the sensory hypoalgesia associated with DPN.This work was supported by grants from the Juvenile Diabetes Research Foundation and the National Institutes of Health [NS054847 and DK073594] (to R.T.D.) and [CA120458 and CA109265] (to B.S.J.B.)
Effect of co-trimoxazole on mortality in HIV-exposed but uninfected children in Botswana (the Mpepu Study): a double-blind, randomised, placebo-controlled trial
Background Co-trimoxazole prophylaxis reduces mortality among HIV-infected children, but efficacy in HIV-exposed
but uninfected (HEU) children in a non-malarial, low-breastfeeding setting with a low risk of mother-to-child
transmission of HIV is unclear.
Methods HEU children in Botswana were randomly assigned to receive co-trimoxazole (100 mg/20 mg once daily until
age 6 months and 200 mg/40 mg once daily thereafter) or placebo from age 14–34 days to age 15 months. Mothers
chose whether to breastfeed or formula feed their children. Breastfed children were randomly assigned to breastfeeding
for 6 months (Botswana guidelines) or 12 months (WHO guidelines). The primary outcome, analysed by a modified
intention-to-treat approach, was cumulative child mortality from treatment assignment to age 18 months. We also
assessed HIV-free survival by duration of breastfeeding. This trial is registered with ClinicalTrials.gov,
number NCT01229761.
Findings From June 7, 2011, to April 2, 2015, 2848 HEU children were randomly assigned to receive co-trimoxazole
(n=1423) or placebo (n=1425). The data and safety monitoring board stopped the study early because of a low likelihood
of benefit with co-trimoxazole. Only 153 (5%) children were lost to follow-up (76 in the co-trimoxazole group and 77 in
the placebo group), and 2053 (72%) received treatment continuously to age 15 months, death, or study closure.
Mortality after the start of study treatment was similar in the two study groups: 30 children died in the co-trimoxazole
group, compared with 34 in the placebo group (estimated mortality at 18 months 2·4% vs 2·6%; difference –0·2%,
95% CI –1·5 to 1·0, p=0·70). We saw no difference in hospital admissions between groups (12·5% in the cotrimoxazole
group vs 17·4% in the placebo group, p=0·19) or grade 3–4 clinical adverse events (16·5% vs 18·4%,
p=0·18). Grade 3–4 anaemia did not differ between groups (8·1% vs 8·3%, p=0·93), but grade 3–4 neutropenia was
more frequent in the co-trimoxazole group than in the placebo group (8·1% vs 5·8%, p=0·03). More co-trimoxazole
resistance in commensal Escherichia coli isolated from stool samples was seen in children aged 3 or 6 months in the
co-trimoxazole group than in the placebo group (p=0·001 and p=0·01, respectively). 572 (20%) children were
breastfed. HIV infection and mortality did not differ significantly by duration of breastfeeding (3·9% for 6 months vs
1·9% for 12 months, p=0·21).
Interpretation Prophylactic co-trimoxazole seems to offer no survival benefit among HEU children in non-malarial,
low-breastfeeding areas with a low risk of mother-to-child transmission of HIV
Recommended from our members
Cotrimoxazole Prophylaxis and Risk of Severe Anemia or Severe Neutropenia in HAART-Exposed, HIV-Uninfected Infants
Background: Prophylactic cotrimoxazole is recommended for infants born to HIV-infected mothers. However, cotrimoxazole may increase the risk of severe anemia or neutropenia. Methods: We compared the proportion of HIV-exposed uninfected (HIV-EU) infants experiencing incident severe anemia (and separately, severe neutropenia) between a prospective cohort receiving prophylactic cotrimoxazole from 1 to 6 months vs. infants from two prior trials who did not receive cotrimoxazole. Infants were from rural and urban communities in southern Botswana. Results: A total of 1705 HIV-EU infants were included. Among these 645 (37.8%) were fed with iron-supplemented formula from birth. Severe anemia developed in 87 (5.1%) infants, and severe neutropenia in 164 (9.6%) infants. In an analysis stratified by infant feeding method, there were no significant differences in the risk of severe anemia by prophylactic cotrimoxazole exposure–risk difference, −0.69% (95% confidence interval [CI] −2.1 to 0.76%). Findings were similar in multivariable analysis, adjusted odds ratio (aOR) 0.35 (95% CI 0.07 to 1.65). There were also no significant differences observed for severe neutropenia by cotrimoxazole exposure, risk difference 2.0% (95% CI −1.3 to 5.2%) and aOR 0.80 (95% CI 0.33 to 1.93). Conclusions: Severe anemia and severe neutropenia were infrequent among HIV-exposed uninfected infants receiving cotrimoxazole from 1–6 months of age. Concerns regarding hematologic toxicity should not limit the use of prophylactic cotrimoxazole in HIV-exposed uninfected infants. ClinicalTrials.gov Registration Numbers NCT01086878 (http://clinicaltrials.gov/show/NCT01086878), NCT00197587 (http://clinicaltrials.gov/show/NCT00197587), and NCT00270296 (http://clinicaltrials.gov/show/NCT00270296)
Inhibiting heat-shock protein 90 reverses sensory hypoalgesia in diabetic mice
Increasing the expression of Hsp70 (heat-shock protein 70) can inhibit sensory neuron degeneration after axotomy. Since the onset of DPN (diabetic peripheral neuropathy) is associated with the gradual decline of sensory neuron function, we evaluated whether increasing Hsp70 was sufficient to improve several indices of neuronal function. Hsp90 is the master regulator of the heat-shock response and its inhibition can up-regulate Hsp70. KU-32 (N-{7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyl-tetrahydro-2H-pyran-2-yloxy]-8-methyl-2-oxo-2H-chromen-3-yl}acetamide) was developed as a novel, novobiocin-based, C-terminal inhibitor of Hsp90 whose ability to increase Hsp70 expression is linked to the presence of an acetamide substitution of the prenylated benzamide moiety of novobiocin. KU-32 protected against glucose-induced death of embryonic DRG (dorsal root ganglia) neurons cultured for 3 days in vitro. Similarly, KU-32 significantly decreased neuregulin 1-induced degeneration of myelinated Schwann cell DRG neuron co-cultures prepared from WT (wild-type) mice. This protection was lost if the co-cultures were prepared from Hsp70.1 and Hsp70.3 KO (knockout) mice. KU-32 is readily bioavailable and was administered once a week for 6 weeks at a dose of 20 mg/kg to WT and Hsp70 KO mice that had been rendered diabetic with streptozotocin for 12 weeks. After 12 weeks of diabetes, both WT and Hsp70 KO mice developed deficits in NCV (nerve conduction velocity) and a sensory hypoalgesia. Although KU-32 did not improve glucose levels, HbA1c (glycated haemoglobin) or insulin levels, it reversed the NCV and sensory deficits in WT but not Hsp70 KO mice. These studies provide the first evidence that targeting molecular chaperones reverses the sensory hypoalgesia associated with DPN
Novel Calicivirus Identified in Rabbits, Michigan, USA
This virus is distinct from rabbit hemorrhagic disease virus
Validation and assessment of an antibiotic-based, aseptic decontamination manufacturing protocol for therapeutic, vacuum-dried human amniotic membrane
© 2019, The Author(s). Amniotic membrane (AM) is used to treat a range of ophthalmic indications but must be presented in a non-contaminated state. AM from elective caesarean sections contains natural microbial contamination, requiring removal during processing protocols. The aim of this study was to assess the ability of antibiotic decontamination of AM, during processing by innovative low-temperature vacuum-drying. Bioburden of caesarean section AM was assessed, and found to be present in low levels. Subsequently, the process for producing vacuum-dried AM (VDAM) was assessed for decontamination ability, by artificially loading with Staphylococcus epidermidis at different stages of processing. The protocol was highly efficient at removing bioburden introduced at any stage of processing, with antibiotic treatment and drying the most efficacious steps. The antibacterial activity of non-antibiotic treated AM compared to VDAM was evaluated using minimum inhibitory/biocidal concentrations (MIC/MBC), and disc diffusion assays against Meticillin-resistant Staphylococcus aureus, Meticillin-resistant S. epidermidis, Escherichia coli, Pseudomonas aeruginosa and Enterococcus faecalis. Antibacterial activity without antibiotic was low, confirmed by high MIC/MBC, and a no inhibition on agar lawns. However, VDAM with antibiotic demonstrated effective antibacterial capacity against all bacteria. Therefore, antibiotic decontamination is a reliable method for sterilisation of AM and the resultant antibiotic reservoir is effective against gram-positive and –negative bacteria
- …